Oniria Therapeutics, a Barcelona, Spain-based biotechnology company that develops drugs for eliminating persistent tumour cells that remain after conventional treatment, raised €1.28M in Seed funding.
The round was led by Mind the Gap, the Botin Foundation’s biotechnology entrepreneurship programme, with participation from BStartup of Banco Sabadell, plus business angels and public funding.
The company intends to use the funds to continue advancing development of ONR-001, a first-in-class drug for eliminating persistent tumour cells that remain after conventional treatment.
Led by CEO Esther Riambau, Oniria Therapeutics is a biopharmaceutical company in the preclinical phase that is developing drugs in the field of precision oncology to eliminate persistent tumour cells, which are responsible for patients progressing into the fatal phases of cancer.
The company was established in 2021 as a spin-off of the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona (UB) and ICREA by Dr Héctor G. Palmer, Esther Riambau, Dr Isabel Puig, Dr Josep Tabernero, Dr Xavier Barril and Dr Carles Galdeano.
FinSMEs
11/05/2023